Literature DB >> 23238327

D3 dopamine receptors interact with dopamine D1 but not D4 receptors in the GABAergic terminals of the SNr of the rat.

Refugio Cruz-Trujillo1, Arturo Avalos-Fuentes, Claudia Rangel-Barajas, Francisco Paz-Bermúdez, Arturo Sierra, Erick Escartín-Perez, Jorge Aceves, David Erlij, Benjamín Florán.   

Abstract

The firing rate of substantia nigra reticulata (SNr) neurons is modulated by GABA release from striatonigral and pallidonigral projections. This release is, in turn, modulated by dopamine acting on dopamine D1 receptors at striatonigral terminals and D4 receptors at pallidonigral terminals. In addition, striatal neurons that express D1 receptors also express D3 receptors. In this study we analyzed the possible significance of D3 and D1 receptor colocalization in striatonigral projections. We found that these receptors coprecipitate in SNr synaptosomes suggesting their close association in this structure. D1 agonist SKF 38393 administered alone increased mIPSC frequency in SNr slices and cAMP production in SNr synaptosomes, however, the selective D3 agonist PD 128,907 increased mIPSC frequency and cAMP production only when D1 receptors were concurrently stimulated. The D1 antagonist SCH 23390 blocked completely the effects of the concurrent administration of these agonists while the selective D3 antagonist GR 103691 blocked only the potentiating effects of PD 128,907. These findings further indicate that D1 and D3 receptors are localized in the same structure. The D4 agonist PD 168,077 decreased mIPSCs frequency without changing amplitude, an effect that was blocked by the selective D4 antagonist L 745,870. The effects of D4 receptor stimulation disappeared after lesioning the globus pallidus. D3 agonist PD 128,907 did not reduce mIPSC frequency even in neurons that responded to D4 agonist. In sum, activation of D3 receptors in SNr potentiates the stimulation of transmitter release and cAMP production caused by D1 receptor activation of striatonigral projections while it is without effects in terminals, probably of pallidal origin, that are inhibited by activation of D4 receptors.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238327     DOI: 10.1016/j.neuropharm.2012.11.032

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  15 in total

Review 1.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 2.  Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?

Authors:  Pengfei Yang; Joel S Perlmutter; Tammie L S Benzinger; John C Morris; Jinbin Xu
Journal:  Ageing Res Rev       Date:  2019-11-22       Impact factor: 10.895

3.  Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.

Authors:  Oscar Solís; Jose Ruben Garcia-Montes; Aldo González-Granillo; Ming Xu; Rosario Moratalla
Journal:  Cereb Cortex       Date:  2017-01-01       Impact factor: 5.357

Review 4.  Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.

Authors:  Christopher J Earley; George R Uhl; Stefan Clemens; Sergi Ferré
Journal:  Sleep Med       Date:  2016-06-27       Impact factor: 3.492

5.  Morphine responsiveness to thermal pain stimuli is aging-associated and mediated by dopamine D1 and D3 receptor interactions.

Authors:  Sophia Samir; Alexander P Yllanes; Perrine Lallemand; Kori L Brewer; Stefan Clemens
Journal:  Neuroscience       Date:  2017-02-28       Impact factor: 3.590

6.  Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat.

Authors:  Kathryn Lanza; Katherine Chemakin; Sarah Lefkowitz; Carolyn Saito; Nicole Chambers; Christopher Bishop
Journal:  Psychopharmacology (Berl)       Date:  2019-08-21       Impact factor: 4.530

7.  Dopaminergic modulation of locomotor network activity in the neonatal mouse spinal cord.

Authors:  Simon A Sharples; Jennifer M Humphreys; A Marley Jensen; Sunny Dhoopar; Nicole Delaloye; Stefan Clemens; Patrick J Whelan
Journal:  J Neurophysiol       Date:  2015-02-04       Impact factor: 2.714

Review 8.  Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia.

Authors:  Oscar Solís; Rosario Moratalla
Journal:  J Neural Transm (Vienna)       Date:  2018-02-07       Impact factor: 3.575

9.  Behavioral and cellular dopamine D1 and D3 receptor-mediated synergy: Implications for L-DOPA-induced dyskinesia.

Authors:  Kathryn Lanza; Samantha M Meadows; Nicole E Chambers; Emily Nuss; Molly M Deak; Sergi Ferré; Christopher Bishop
Journal:  Neuropharmacology       Date:  2018-06-21       Impact factor: 5.273

10.  Dopamine D3 receptor dysfunction prevents anti-nociceptive effects of morphine in the spinal cord.

Authors:  Kori L Brewer; Christine A Baran; Brian R Whitfield; A Marley Jensen; Stefan Clemens
Journal:  Front Neural Circuits       Date:  2014-06-11       Impact factor: 3.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.